Dr. Sagal Lonial on an Iberdomide Combination Therapy
In this video:
Iberdomide (IBER) is an oral, novel cereblon E3 ligase modulator (CELMoD) compound with marked synergistic tumoricidal and immune-stimulatory effects in combination with proteasome inhibitors (PIs) or anti-CD38 monoclonal antibodies, preclinically and clinically. CC-220-MM-001 (NCT02773030) is an ongoing phase 1/2 study evaluating the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, and preliminary efficacy of IBER with different treatment combinations in independent cohorts, in patients with relapsed refractory multiple myeloma (RRMM).
In this video:
Dr. Sagar Lonial (Winship Cancer Institute, Atlanta, Georgia, USA) discusses the results of Iberdomide in combination with dexamethasone and daratummab, bortezomib, or carfilzomib in relapsed refractory multiple myeloma.
Conclusions:
In heavily pretreated patients with RRMM, IberDd, IberVd, and IberKd showed a manageable safety profile and promising efficacy including CRs, even among DARA- and BORT-refractory patients. The study is ongoing. These results support further development of IBER-based regimens in multiple myeloma, including the initiation of phase 3 combination studies.
